5-Amino-1MQsafety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for 5-Amino-1MQ as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. 5-Amino-1MQ is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

5-Amino-1MQ's safety dataset is limited to pre-clinical work — there are no published human clinical-trial data. The pre-clinical safety record across rodent obesity and skeletal-muscle studies has been favourable: oral doses of 50-200 mg/kg/day over 10-12 weeks produced no overt toxicity, no significant changes in routine haematology or hepatic enzymes beyond expected age-related drift, and no documented organ-specific lesions in standard histopathology. Theoretical safety considerations centre on the NNMT pathway's broader biological roles. NNMT is expressed at modest baseline levels in many tissues and contributes to methyl-donor metabolism, nicotinamide handling, and (through 1-methylnicotinamide as a signalling molecule) to vascular and inflammatory regulation. Chronic systemic NNMT inhibition could theoretically affect tissues beyond the adipose and skeletal-muscle research targets. The pre-clinical absence of overt off-target toxicity is reassuring but the pharmacological space is incompletely characterised. Methylation-dependent processes (DNA methylation, histone methylation, neurotransmitter synthesis) might theoretically be affected by chronic NNMT inhibition through SAM-pool effects. The pre-clinical work has not identified clinically significant methylation perturbations at research doses, but human chronic dosing has not been performed. Formulation safety for the iodide salt — the standard research-chemical form — should consider iodide-pool effects in chronic dosing. The iodide counter-ion is not biologically inert and chronic high-dose oral 5-Amino-1MQ iodide could plausibly contribute to iodine-pool changes affecting thyroid function. Research protocols should consider alternative salt forms or iodide-pool monitoring for chronic-dosing studies. No serious adverse events have been documented in any published 5-Amino-1MQ research. The acute safety profile in research animals is favourable; chronic and human safety remains uncharacterised.

UK regulatory status

5-Amino-1MQ is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. The compound is a small molecule rather than a peptide, but the regulatory framework applicable in the UK is the same — supply or administration to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. Research-grade material for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. 5-Amino-1MQ is not currently on the WADA Prohibited List. The compound's mechanism (NNMT inhibition affecting adipose and skeletal-muscle metabolism) does not currently fall within any WADA category, but athletes should verify the current annual Prohibited List as classifications can change with emerging compounds. For animal research under ASPA, 5-Amino-1MQ work in vertebrates requires standard project and personal licences from the Home Office Drugs and Firearms Licensing Unit.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. 5-Amino-1MQ is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full 5-Amino-1MQ research context including mechanism, study citations, and references, see the main 5-Amino-1MQ research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.